AFM
DMK

Anson Funds Management’s DMK Pharmaceuticals Corporation Common Stock DMK Stock Holding History

Anson Funds Management’s Portfolio DMK Stock Details DMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-43,044
Closed -$2.74M – 92
2020
Q1 		$2.74M Buy
+43,044
New +$1.83M 1.12% 14
2019
Q4 		– Sell
-20,637
Closed -$1.02K – 90
2019
Q3 		$1.02K Buy
+20,637
New +$1.48M 0.75% 15

Other funds holding DMK

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
LFAS
Level Four Advisory Services Dallas, Texas $3.05B AUM 23.96% 1-Year Est. Return

Anson Funds Management's DMK Position: Q2 2020 in Review

Anson Funds Management sold out of DMK Pharmaceuticals Corporation Common Stock (DMK) in Q2 2020, closing a stake of 43,044 shares — an estimated $2.74M sold.

Anson Funds Management first reported a position in DMK in Q3 2019 and held it in 2 quarters. The position peaked at $2.74M in Q1 2020. 47 funds tracked by Wall St. Rank hold DMK as of Q2 2020.

  • Anson Funds Management reported no remaining DMK Pharmaceuticals Corporation Common Stock position as of Q2 2020 after selling out during the quarter.
  • Anson Funds Management sold 43,044 DMK Pharmaceuticals Corporation Common Stock shares in Q2 2020, an estimated $2.74M.
  • Anson Funds Management first reported a position in DMK Pharmaceuticals Corporation Common Stock in Q3 2019 and held it in 2 quarters.
  • Anson Funds Management's DMK Pharmaceuticals Corporation Common Stock position peaked at $2.74M in Q1 2020.
  • 47 funds tracked by Wall St. Rank held DMK Pharmaceuticals Corporation Common Stock as of Q2 2020.

Based on Anson Funds Management's 13F filing for Q2 2020, filed 12 Aug 2020.